Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 4
2009 7
2010 10
2011 3
2012 3
2013 1
2014 2
2015 2
2016 6
2017 5
2018 3
2019 5
2020 4
2021 9
2022 10
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles GA, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano JM, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ. Zinzani PL, et al. Among authors: johnson na. Blood Adv. 2024 Mar 26:bloodadvances.2023011030. doi: 10.1182/bloodadvances.2023011030. Online ahead of print. Blood Adv. 2024. PMID: 38531062 No abstract available.
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments.
Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SEJ, Huang F, Chou H, Gagnon N, Johnson NA, Miller WH, Mann KK, Del Rincon SV. Abraham MJ, et al. Among authors: johnson na. Cell Biosci. 2024 Feb 4;14(1):19. doi: 10.1186/s13578-024-01199-4. Cell Biosci. 2024. PMID: 38311785 Free PMC article.
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Benoit A, Abraham MJ, Li S, Kim J, Estrada-Tejedor R, Bakadlag R, Subramaniam N, Makhani K, Guilbert C, Tu R, Salaciak M, Klein KO, Coyle KM, Hilton LK, Santiago R, Dmitrienko S, Assouline S, Morin RD, Del Rincon SV, Johnson NA, Mann KK. Benoit A, et al. Among authors: johnson na. Int J Hematol. 2024 Mar;119(3):275-290. doi: 10.1007/s12185-023-03692-x. Epub 2024 Jan 29. Int J Hematol. 2024. PMID: 38285120 Free PMC article.
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
Banerji V, Aw A, Laferriere N, Abdel-Samad N, Peters A, Johnson NA, Bernard MP, Gopalakrishnan S, Bull SJ, Fournier PA, Klil-Drori AJ, Hay AE, Robinson S, Owen C. Banerji V, et al. Among authors: johnson na. Leuk Lymphoma. 2024 May;65(5):609-617. doi: 10.1080/10428194.2024.2301738. Epub 2024 Jan 18. Leuk Lymphoma. 2024. PMID: 38235709
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Herrera AF, Lin J, Kim E, Chakraborty S, Marinello P, Moskowitz CH. Armand P, et al. Among authors: johnson na. Blood. 2023 Sep 7;142(10):878-886. doi: 10.1182/blood.2022019386. Blood. 2023. PMID: 37319435 Free PMC article.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Lasater EA, Amin DN, Bannerji R, Mali RS, Barrett K, Rys RN, Oeh J, Lin E, Sterne-Weiler T, Ingalla ER, Go M, Yu SF, Krem MM, Arthur C, Hahn U, Johnston A, Karur V, Khan N, Marlton P, Phillips T, Gritti G, Seymour JF, Tani M, Yuen S, Martin S, Chang MT, Rose CM, Pham VC, Polson AG, Chang Y, Wever C, Johnson NA, Jiang Y, Hirata J, Sampath D, Musick L, Flowers CR, Wertz IE. Lasater EA, et al. Among authors: johnson na. Am J Hematol. 2023 Mar;98(3):449-463. doi: 10.1002/ajh.26809. Epub 2023 Jan 17. Am J Hematol. 2023. PMID: 36594167 Free article. Clinical Trial.
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Fooks K, Galicia-Vazquez G, Gife V, Schcolnik-Cabrera A, Nouhi Z, Poon WWL, Luo V, Rys RN, Aloyz R, Orthwein A, Johnson NA, Hulea L, Mercier FE. Fooks K, et al. Among authors: johnson na. J Exp Clin Cancer Res. 2022 Dec 9;41(1):340. doi: 10.1186/s13046-022-02542-8. J Exp Clin Cancer Res. 2022. PMID: 36482393 Free PMC article.
CD73 Promotes Chronic Lymphocytic Leukemia.
Allard D, Chrobak P, Bareche Y, Allard B, Tessier P, Bergeron MA, Johnson NA, Stagg J. Allard D, et al. Among authors: johnson na. Cancers (Basel). 2022 Jun 26;14(13):3130. doi: 10.3390/cancers14133130. Cancers (Basel). 2022. PMID: 35804900 Free PMC article.
76 results